Detalhe da pesquisa
1.
High grade adverse event reporting and enrolment in gynecologic oncology clinical trials.
Gynecol Oncol
; 185: 1-7, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38342004
2.
Electronic malignant bowel obstruction symptom monitoring smartphone application for patients with gynecologic cancers.
Int J Gynecol Cancer
; 2024 May 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-38821545
3.
A phase I study of the Wee1 kinase inhibitor adavosertib (AZD1775) in combination with chemoradiation in cervical, upper vaginal, and uterine cancers.
Int J Gynecol Cancer
; 33(8): 1208-1214, 2023 08 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37380217
4.
Management of Malignant Bowel Obstruction: An Innovative Proactive Outpatient Nurse-Led Model of Care for Patients With Advanced Gynecologic Cancer.
J Nurs Care Qual
; 38(1): 69-75, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36214674
5.
Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial.
Lancet
; 397(10271): 281-292, 2021 01 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-33485453
6.
Patient self-reporting of tolerability using PRO-CTCAE in a randomized double-blind, placebo-controlled phase II trial comparing gemcitabine in combination with adavosertib or placebo in patients with platinum resistant or refractory epithelial ovarian carcinoma.
Gynecol Oncol
; 167(2): 226-233, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36055813
7.
Research biopsies in patients with gynecologic cancers: patient-reported outcomes, perceptions, and preferences.
Am J Obstet Gynecol
; 225(6): 658.e1-658.e9, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34174204
8.
Supported self-management as a model for end-of-life care in the setting of malignant bowel obstruction: A qualitative study.
Gynecol Oncol
; 157(3): 745-753, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32217004
9.
Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events.
Int J Gynecol Cancer
; 30(7): 903-915, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32276934
10.
Corrigendum to Research biopsies in patients with gynecologic cancers: patient-reported outcomes, perceptions, and preferences: Am J Obstet Gynecol 225 (2021) 658.e1-658.e9/Article 658.
Am J Obstet Gynecol
; 231(1): 141, 2024 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-38679558
11.
Resisting RECIST-Uniformity Versus Clinical Validity.
Int J Gynecol Cancer
; 27(8): 1619-1627, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28692635
12.
Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma.
Nat Commun
; 14(1): 1452, 2023 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36922497
13.
Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression.
Clin Cancer Res
; 29(18): 3706-3716, 2023 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37327320
14.
Repurposing Itraconazole and Hydroxychloroquine to Target Lysosomal Homeostasis in Epithelial Ovarian Cancer.
Cancer Res Commun
; 2(5): 293-306, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36875717
15.
EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression.
Clin Cancer Res
; 26(16): 4206-4215, 2020 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32444417
16.
Optimizing the Care of Malignant Bowel Obstruction in Patients With Advanced Gynecologic Cancer.
J Oncol Pract
; 15(12): e1066-e1075, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31550202
17.
Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition.
J Clin Oncol
; 35(11): 1240-1249, 2017 Apr 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28221868
18.
Ovarian Cancer and BRCA1/2 Testing: Opportunities to Improve Clinical Care and Disease Prevention.
Front Oncol
; 6: 119, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27242959
19.
Safety evaluation of olaparib for treating ovarian cancer.
Expert Opin Drug Saf
; 14(8): 1305-16, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-26051946